Genmab A/S (LON:0MGB)
United Kingdom · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 25.70B +91.8% |
| Revenue (ttm) | 3.24B +11.7% |
| Net Income | 549.10M -54.0% |
| EPS | 8.61 -53.4% |
| Shares Out | n/a |
| PE Ratio | 47.11 |
| Forward PE | 31.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,650 |
| Open | 3,700.00 |
| Previous Close | 3,661.00 |
| Day's Range | 3,596.00 - 3,702.00 |
| 52-Week Range | 1,514.50 - 3,943.00 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The inc...
Genmab Transcript: 8th Annual Wolfe Research Healthcare Conference
Three positive Phase III readouts included an EPKINLY frontline DLBCL HR of 0.49 and OS benefits for Rina-S and petosemtamab. Peak-sales estimates stand at >$3B for EPKINLY, >$2B for Rina-S and multi-billion for petosemtamab, with launches and regulatory filings now the focus.
Genmab (GMAB) Q3 2026 Earnings Call Transcript
Strong royalties and pipeline progress, but litigation risks remain in focus.
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
Genmab A/S NASDAQ: GMAB reported 22% revenue growth for the first nine months of 2026 and said it expects full-year revenue to land in the upper part of its existing guidance range, as sales of EPKINL...
Genmab Earnings Call Transcript: Q3 2026
9M revenue grew 22% and adjusted operating profit rose 9%, supported by broad portfolio growth. Three positive phase III readouts strengthen the late-stage pipeline, while FY26 guidance is maintained and 2027 priorities include profit growth and gross leverage below 3x.
Genmab Quarterly report: Q3 2026
Genmab has published its Q3 2026 quarterly earnings report on November 5, 2026.
Genmab Earnings release: Q3 2026
Genmab released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Genmab Slides: Q3 2026
Genmab has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Genmab reports 9M revenue $3.24B vs. $2.66B last year
Royalty revenue was $2.7B in the first nine months of 2026 compared to $2.22B in the first nine months of 2025, an increase of $480M, or 22%. The increase in…
Genmab backs 2026 financial guidance
11:05 EST Genmab (GMAB) backs 2026 financial guidance
Genmab Slides: Investor presentation
Genmab has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that 22 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or publi...
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
Genmab shares have doubled in three months after three successful Phase 3 cancer drug trials in October. The Danish biotech is using royalty income from drugs such as Darzalex to fund a shift toward o...
Genmab price target raised to DKK 4,400 from DKK 4,200 at BofA
BofA analyst Charlie Haywood raised the firm’s price target on Genmab (GMAB) to DKK 4,400 from DKK 4,200 and keeps a Buy rating on the shares. After 3/3 positive Phase…
Genmab price target raised to $57 from $42 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Genmab (GMAB) to $57 from $42 and keeps an Equal Weight rating on the shares.
Genmab price target raised to $80 from $58 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $80 from $58 and keeps a Buy rating on the shares.
Bicara Therapeutics price target lowered to $24 from $33 at Wedbush
Wedbush analyst David Nierengarten lowered the firm’s price target on Bicara Therapeutics (BCAX) to $24 from $33 and keeps an Outperform rating on the shares. Relevant to Bicara, Genmab’s (GMAB)…
Genmab price target raised to $70 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $70 from $50 and keeps a Buy rating on the shares. The company announced positive top-line results from the…
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the comp...
Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%
(RTTNews) - Shares of several biotech companies moved higher following quarterly financial results, clinical trial developments and business updates. Genmab reported positive Phase 3 results for its c...
Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for Its Head and Neck Cancer Treatment
Genmab stock saw an over 30% rally on Wednesday following a clinical trial update for its head and neck cancer drug.
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
Genmab Transcript: Study result
Three phase III programs reported positive results across DLBCL, platinum-resistant ovarian and head and neck cancers. Petosemtamab colorectal data support further development, with potential launches beginning in 2027.
Genmab Press release: Study result
Genmab issued a press release on October 28, 2026, disclosing material business information to investors.